A new peer-reviewed study shows that the Belay Summit cerebrospinal fluid (CSF)-based liquid biopsy test informed clinical ...

CHICAGO, March 24, 2026 /PRNewswire/ -- Belay Diagnostics announced the publication of a new retrospective study demonstrating that its Summit and Vantage tests provided meaningful clinical impact in ...

Delve Bio, a UCSF spin-out and pioneer in metagenomic next-generation sequencing (mNGS) for infectious diseases, announced data underscoring the clinical impact of mNGS using Delve Detect to identify ...

(MENAFN- Investor Brand Network) Primary and metastatic central nervous system (CNS) tumors can have extraordinary biological and anatomical complexity, and these tumors can be hard to identify using ...

Oligonucleotide (oligo) therapies have been in development for decades. Recent advances in molecular design, chemistry, ...

-Delve Bio to Present Two Oral Presentations at American Academy of Neurology 2026 Annual Meeting- Delve Bio, a UCSF spin-out and pioneer in metagenomic next-generation sequencing (mNGS) for ...